Design, synthesis and biological activity of 7-O-(4-O-acetyl-3-iodo-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl)daunomycinone and 7-O-(3-chloro-2,3,6-trideoxy-4-O-propanoyl-alpha-L-lyxo-hexopyranosyl)daunomycinone

Authors
Aligiannis, N Pouli, N Marakos, P Mitaku, S Skaltsounis, AL Leonce, S Pierre, A Atassi, G
Citation
N. Aligiannis et al., Design, synthesis and biological activity of 7-O-(4-O-acetyl-3-iodo-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl)daunomycinone and 7-O-(3-chloro-2,3,6-trideoxy-4-O-propanoyl-alpha-L-lyxo-hexopyranosyl)daunomycinone, CHEM PHARM, 48(1), 2000, pp. 150-153
Citations number
16
Categorie Soggetti
Chemistry & Analysis
Journal title
CHEMICAL & PHARMACEUTICAL BULLETIN
ISSN journal
00092363 → ACNP
Volume
48
Issue
1
Year of publication
2000
Pages
150 - 153
Database
ISI
SICI code
0009-2363(200001)48:1<150:DSABAO>2.0.ZU;2-3
Abstract
The synthesis and pharmacological evaluation of 7-O-(4-O-acetyl-3-iodo-2,3, 6-trideoxy-alpha-L-arabino-hepoxy-ranosyl)daunomycinone and 7-O-(3-chloro-2 ,3,6-trideoxy-4-O-propanoyl-alpha-L-lyxo-hexopyranosyl)daunomycinone are de scribed. Their cytotoxic activity was evaluated against normal and resistan t cell lines. Both compounds exhibited activity against the adriamycin resi stant cell line KB-A1. These results support the hypothesis that the increa sed lipophilicity of the sugar part of anthracyclines is associated with th eir ability to overcome multidrug resistance (MDR).